Yes, I guess the hope was that OPT302 might broaden the number of patients who respond, and the CEO frequently mentioned the high proportion who failed to respond to anti VEGF-A.
But the results are in line with the theory that there is a strong link between response to VEGF-A and VEGF-C and D targeted by OPT302.
So actually, it's a result that might be expected. Not a bad result, but not an unexpectedly good surprise.
Anyway, lets see what big pharma make of it. Interested, or not.
Ann: Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME, page-41
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
88.0¢ |
Change
-0.015(1.68%) |
Mkt cap ! $1.064B | |||
| Open | High | Low | Value | Volume |
| 88.5¢ | 88.5¢ | 85.8¢ | $2.379M | 2.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 146634 | 87.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 88.0¢ | 20878 | 29 |
View Market Depth
| Last trade - 15.19pm 08/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |